Gastro Medical News

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis
Inflammatory Bowel Disease, 09/03/09

Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitisDaniel C. Baumgart, MD 1 *, Stephan R. Targan, MD 2, Axel U. Dignass, MD 3, Lloyd Mayer, MD 4, Gert van Assche, MD 5, Daan W. Hommes, MD 6, Stephen B. Hanauer, MD 7, Uma Mahadevan, MD 8, Walter Reinisch, MD 9, Scott E. Plevy, MD 10, Bruce A. Salzberg, MD 11, Alan L. Buchman, MD 12, Grigor M. Mechkov, MD 13, Zahariy A. Krastev, MD 14, James N. Lowder, MD 15, Matthew B. Frankel, MD 15, William J. Sandborn, MD 161Departments of Medicine, Divisions of Gastroenterology and Hepatology, Charité Medical School of the Humboldt-University of Berlin, Germany2Departments of Medicine, Divisions of Gastroenterology and Hepatology, Cedars Sinai Medical Center, University of California, Los Angeles, CA, USA3Departments of Medicine, Divisions of Gastroenterology and Hepatology, Markuskrankenhaus, Frankfurt, Germany4Departments of Medicine, Divisions of Gastroenterology and Hepatology, Mount Sinai School of Medicine, New York, NY, USA5Departments of Medicine, Divisions of Gastroenterology and Hepatology, Universitaire Ziekenhuizen Gasthuisberg, Leuven, Belgium6Departments of Medicine, Divisions of Gastroenterology and Hepatology, University of Leiden, Leiden, The Netherlands7Departments of Medicine, Divisions of Gastroenterology and Hepatology, University of Chicago, Chicago, IL, USA8Departments of Medicine, Divisions of Gastroenterology and Hepatology, University of California San Francisco, CA, USA9Departments of Medicine, Divisions of Gastroenterology and Hepatology, Medizinische Universität Wien, Vienna, Austria10Departments of Medicine, Divisions of Gastroenterology and Hepatology, University of Pittsburgh, Pittsburgh, PA, USA11Departments of Medicine, Divisions of Gastroenterology and Hepatology, Atlanta Gastroenterology Associates, Atlanta, GA, USA12Departments of Medicine, Divisions of Gastroenterology and Hepatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA13Departments of Medicine, Divisions of Gastroenterology and Hepatology, Military Medical Academy, Sofia, Bulgaria14Departments of Medicine, Divisions of Gastroenterology and Hepatology. University of Sofia, Sofia, Bulgaria15Departments of Medicine, Divisions of Gastroenterology and Hepatology, Facet Biotech Corp. (formerly Protein Design Labs and then PDL BioPharma), Redwood City, CA16Departments of Medicine, Divisions of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USAemail: Daniel C. Baumgart (daniel.

<< Previous
Widespread but not localized neoplasia in inflammatory bowel...

Next >>
Hepatitis C Virus Sensitivity to Combined Antiviral Therapy in...